Breakthroughs in Hepatitis C Research: from Discovery to Cure

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2022 May 20

PMID 35595834

Authors

Michael P Manns

Benjamin Maasoumy

Affiliations

Soon will be listed here.

Abstract

In the 1970s, an unknown virus was suspected for documented cases of transfusion-associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious transmissible agent was identified and named hepatitis C virus (HCV) and, soon enough, the first diagnostic HCV antibody test was developed, which led to a dramatic decrease in new infections. Today, HCV infection remains a global health burden and a major cause of liver cirrhosis, hepatocellular carcinoma and liver transplantation. However, tremendous advances have been made over the decades, and HCV became the first curable, chronic viral infection. The introduction of direct antiviral agents revolutionized antiviral treatment, leading to viral eradication in more than 98% of all patients infected with HCV. This Perspective discusses the history of HCV research, which reads like a role model for successful translational research: starting from a clinical observation, specific therapeutic agents were developed, which finally were implemented in national and global elimination programmes.

Citing Articles

Opportunities and challenges for hepatitis B cure.

Roca Suarez A, Zoulim F eGastroenterology. 2025; 1(2):e100021.

PMID: 39944004 PMC: 11731071. DOI: 10.1136/egastro-2023-100021.

High-throughput multiplexed serology via the mass-spectrometric analysis of isotopically barcoded beads.

Drainas A, McIlwain D, Dallas A, Chu T, Delgado-Gonzalez A, Baron M Nat Biomed Eng. 2025; .

PMID: 39939547 DOI: 10.1038/s41551-025-01349-0.

Liver diseases: epidemiology, causes, trends and predictions.

Gan C, Yuan Y, Shen H, Gao J, Kong X, Che Z Signal Transduct Target Ther. 2025; 10(1):33.

PMID: 39904973 PMC: 11794951. DOI: 10.1038/s41392-024-02072-z.

Asian Perspective on Hepatitis B Virus and Hepatitis C Virus Elimination.

Kaewdech A, Charatcharoenwitthaya P, Piratvisuth T Viruses. 2025; 17(1.

PMID: 39861823 PMC: 11768638. DOI: 10.3390/v17010034.

Characterization and Detection Strategy Exploration in Cryptogenic Hepatocellular Carcinoma: Insights From a Super-Aged Region in Japan.

Sugihara T, Nagahara T, Kihara T, Ikeda S, Hoshino Y, Matsuki Y Cancer Med. 2025; 14(2):e70490.

PMID: 39846235 PMC: 11755116. DOI: 10.1002/cam4.70490.

References

Goodkin D, Bieber B, Gillespie B, Robinson B, Jadoul M . Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013; 38(5):405-12. DOI: 10.1159/000355615. View

Colombo M, Kuo G, Choo Q, Donato M, Del Ninno E, Tommasini M . Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989; 2(8670):1006-8. DOI: 10.1016/s0140-6736(89)91016-7. View

Manns M, Samuel D, Gane E, Mutimer D, McCaughan G, Buti M . Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016; 16(6):685-697. DOI: 10.1016/S1473-3099(16)00052-9. View

Kiser J, Burton J, Anderson P, Everson G . Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012; 55(5):1620-8. PMC: 3345276. DOI: 10.1002/hep.25653. View

Hoofnagle J, Mullen K, Jones D, Rustgi V, Di Bisceglie A, Peters M . Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986; 315(25):1575-8. DOI: 10.1056/NEJM198612183152503. View

Samur S, Kues B, Ayer T, Roberts M, Kanwal F, Hur C . Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2017; 16(1):115-122.e10. PMC: 5733714. DOI: 10.1016/j.cgh.2017.06.024. View

Norkrans G, Frosner G, HERMODSSON S, Iwarson S . Multiple hepatitis attacks in drug addicts. JAMA. 1980; 243(10):1056-8. View

Cheung M, Walker A, Hudson B, Verma S, McLauchlan J, Mutimer D . Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; 65(4):741-747. DOI: 10.1016/j.jhep.2016.06.019. View

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H . Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl):S45-57. DOI: 10.1016/j.jhep.2014.07.027. View

10.

La Hoz R, Sandikci B, Ariyamuthu V, Tanriover B . Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am J Transplant. 2019; 19(11):3058-3070. PMC: 6864234. DOI: 10.1111/ajt.15496. View

11.

Afdhal N, Reddy K, Nelson D, Lawitz E, Gordon S, Schiff E . Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370(16):1483-93. DOI: 10.1056/NEJMoa1316366. View

12.

de Kanter C, van Luin M, Solas C, Burger D, Vrolijk J . Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin. Ann Hepatol. 2014; 13(4):452-5. View

13.

Garson J, Brillanti S, Ring C, Perini P, Miglioli M, Barbara L . Hepatitis C viraemia rebound after "successful" interferon therapy in patients with chronic non-A, non-B hepatitis. J Med Virol. 1992; 37(3):210-4. DOI: 10.1002/jmv.1890370311. View

14.

Poordad F, Felizarta F, Asatryan A, Sulkowski M, Reindollar R, Landis C . Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017; 66(2):389-397. PMC: 5573922. DOI: 10.1002/hep.29081. View

15.

Sulkowski M, Jacobson I, Nelson D . Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med. 2014; 370(16):1560-1. DOI: 10.1056/NEJMc1401726. View

16.

Gupta G, Zhang Y, Carroll N, Sterling R . Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. Am J Transplant. 2018; 18(10):2496-2505. DOI: 10.1111/ajt.15054. View

17.

Mangia A, Santoro R, Minerva N, Ricci G, Carretta V, Persico M . Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352(25):2609-17. DOI: 10.1056/NEJMoa042608. View

18.

Maasoumy B, Cobb B, Bremer B, Luk K, Halfon P, Aslam S . Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther. 2013; 39(1):85-92. DOI: 10.1111/apt.12544. View

19.

Sarrazin C, Kieffer T, Bartels D, Hanzelka B, Muh U, Welker M . Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132(5):1767-77. DOI: 10.1053/j.gastro.2007.02.037. View

20.

Roth D, Nelson D, Bruchfeld A, Liapakis A, Silva M, Monsour Jr H . Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015; 386(10003):1537-45. DOI: 10.1016/S0140-6736(15)00349-9. View